News
Clinical Topics
Integrative Care
Global Bulletin
All News
Approval Alert
Media
2 Minute Drill
Around the Practice
Between the Lines
Clinical Consult
Expert Interviews
Face Off
Medical World News
Morning Rounds
OncView
Podcasts
Readout 360
Satellite Sessions
Sponsored Media
Training Academy
Year in Review
Conferences
Publications
All Journals
For Authors
Tumor Board
Events
Frontline Forum
CME/CE
Resources
Contemporary Concepts
Awareness Month
Interactive Tools
Nurse Practitioners/Physician's Assistants
Partners
Sponsored
Subscribe
Print Subscription
eNewsletter

logo
Spotlight
Around the Practice
Between the Lines
Contemporary Concepts
Journal
OncView
Podcasts
Readout 360
2022 ASCO Genitourinary Cancers Symposium Urothelial Cancer Updates
CancerNetwork® Inaugural Face-Off
Contemporary Concepts in Hematologic Oncology
Insights from Experts at Mayo Clinic on Translating Evidence to Clinical Practice
Optimizing Outcomes in Patients with HER2+ Metastatic Breast Cancer
Clinical
Acute Myeloid Leukemia
Brain Cancer
Breast Cancer
Gastrointestinal Cancer
Genitourinary Cancer
Gynecologic Cancer
Hematology
Leukemia
Lung Cancer
Lymphoma
Pediatric Cancers
Skin Cancer
Clinical Topics
Integrative Care
Global Bulletin
All News
Approval Alert
2 Minute Drill
Around the Practice
Between the Lines
Clinical Consult
Expert Interviews
Face Off
Medical World News
Morning Rounds
OncView
Podcasts
Readout 360
Satellite Sessions
Sponsored Media
Training Academy
Year in Review
Conferences
All Journals
For Authors
Tumor Board
Frontline Forum
CME/CE
Contemporary Concepts
Awareness Month
Interactive Tools
Nurse Practitioners/Physician's Assistants
Partners
Sponsored
Print Subscription
eNewsletter
Advertisement
Breast Cancer
| Kidney Cancer
| Leukemia
| Lymphoma
| Multiple Myeloma
| Non-Small Cell Lung Cancer (NSCLC)
| Small Cell Lung Cancer (SCLC)
| Adverse Effects
| Biomarkers
| Bladder Cancer
| Brain Cancer
| Cervical Cancer
| Colorectal Cancer
| Endometrial Cancer
| Esophageal Cancer
| Gastrointestinal Cancer
| Genitourinary Cancers
| Gynecologic Cancers
| Head & Neck Cancer
| Hematology
| Hormone-related Cancers
| Immunotherapy
| Infection
| Liver Cancer
| Lung Cancer
| Mesothelioma
| Neuroendocrine Tumors
| Oncology
| Ovarian Cancer
| Ovarian Cancer Clincal Consult
| Pancreatic Cancer
| Pediatric Cancers
| Prostate Cancer
| Radiation Oncology
| Sarcoma
| Screening
| Skin Cancer & Melanoma
| Surgery
| Thoracic Malignancies
| Thyroid Cancer
View All >>
  • Adverse Effects
  • Biomarkers
  • Bladder Cancer
  • Brain Cancer
  • Breast Cancer
  • Cervical Cancer
  • Colorectal Cancer
  • Endometrial Cancer
  • Esophageal Cancer
  • Gastrointestinal Cancer
  • Genitourinary Cancers
  • Gynecologic Cancers
  • Head & Neck Cancer
  • Hematology
  • Hormone-related Cancers
  • Immunotherapy
  • Infection
  • Kidney Cancer
  • Leukemia
  • Liver Cancer
  • Lung Cancer
  • Lymphoma
  • Mesothelioma
  • Multiple Myeloma
  • Neuroendocrine Tumors
  • Non-Small Cell Lung Cancer (NSCLC)
  • Oncology
  • Ovarian Cancer
  • Ovarian Cancer Clincal Consult
  • Pancreatic Cancer
  • Pediatric Cancers
  • Prostate Cancer
  • Radiation Oncology
  • Sarcoma
  • Screening
  • Skin Cancer & Melanoma
  • Small Cell Lung Cancer (SCLC)
  • Surgery
  • Thoracic Malignancies
  • Thyroid Cancer

SPOTLIGHT -

Around the Practice
| Between the Lines
| Contemporary Concepts
| Journal
| OncView
| Podcasts
| Readout 360
| 2022 ASCO Genitourinary Cancers Symposium Urothelial Cancer Updates
| CancerNetwork® Inaugural Face-Off
| Contemporary Concepts in Hematologic Oncology
| Insights from Experts at Mayo Clinic on Translating Evidence to Clinical Practice
| Optimizing Outcomes in Patients with HER2+ Metastatic Breast Cancer

Despite Trends Towards PFS, OS Improvement, Pembrolizumab/Lenvatinib Trial in HCC Misses Primary End Points

Aug 4, 2022
Hayley Virgil
Article

Although patients with unresectable hepatocellular carcinoma initially appeared to have survival benefit following treatment with pembrolizumab and lenvatinib vs lenvatinib alone, the findings did not meet statistical significance.

Treatment with pembrolizumab (Keytruda) and lenvatinib (Lenvima) appeared to result in some improvement in overall survival (OS) and progression-free survival (PFS) compared with lenvatinib monotherapy in patients with unresectable hepatocellular carcinoma (HCC), however study end points from the phase 3 LEAP-002 trial (NCT03713593) ultimately missed the threshold for significance, according to a press release from Merck.

Despite initially improved outcomes reported from the trial, OS and PFS did not meet statistical significance by the prespecified statistical plan. The median OS of the lenvatinib monotherapy arm in LEAP-002 was longer than what has been observed in previous clinical trials evaluating the single-agent in unresectable HCC.

Data from the trial are set to read out at an upcoming medical conference.

“Our joint clinical development program Keytruda plus Lenvima is designed to address unmet needs for some of the most challenging-to-treat types of cancer, like hepatocellular carcinoma,” Gregory Lubiniecki, MD, vice president of Global Clinical Development at Merck Research Laboratories, said in a press release. “We remain confident in the potential of this combination based on the body of evidence we’ve seen to date and will continue to investigate its role across multiple types of cancer.”

A total of 794 patients were included in the study. Patients in both arms received 8 mg/kg or 12 mg/kg of lenvatinib, with the experimental arm receiving 200 mg of pembrolizumab on day 1 of every 21-day cycle up to a maximum of 35 cycles. Lenvatinib was administered until progressive disease or unacceptable toxicities occurred.

Secondary end points included objective response rate, duration of response, disease control rate, and time to disease progression.

To enroll on the trial, patients were required to have disease confirmed by radiology, histology, or cytology with Barcelona Clinic Liver Cancer Stage C disease or B disease not amenable to locoregional treatment options or refractory to locoregional treatments. A Child-Pugh class A liver score and life expectancy of over 3 months were also required for enrollment.

Those with esophageal or gastric variceal bleeding within the previous 6 months, conditions that might impact lenvatinib absorption, and preexisting grade 3 or higher fistula were not able to enroll. Other exclusion criteria included clinically significant hemoptysis within 2 weeks, significant cardiovascular impairment within 12 months, and major surgery within 4 weeks.

“Aiming for further improvement in the treatment of patients with unresectable HCC, we selected [lenvatinib] monotherapy, a standard of care option, as the control arm of the LEAP-002 trial,” Corina Dutcus, MD, senior vice president of Clinical Research, Oncology at Eisai Inc, concluded. “While results evaluating the combination are not what we had hoped for, we will continue to contribute to the care of patients with unresectable HCC by applying valuable knowledge from the LEAP-002 trial.”

Reference

Merck and Eisai provide update on phase 3 LEAP-002 trial evaluating KEYTRUDA® (pembrolizumab) plus LENVIMA® (lenvatinib) versus LENVIMA monotherapy in patients with unresectable hepatocellular carcinoma. News release. Merck. August 3, 2022. Accessed August 3, 2022. https://bit.ly/3Sq75Jy

Related Videos
Adding radiation to sorafenib elicited a survival improvement in a group of patients with hepatocellular carcinoma, a type of liver cancer.
Future research into the management of unresectable hepatocellular carcinoma may involve combining local therapies with checkpoint inhibitors like durvalumab and tremelimumab, according to Ghassan K. Abou-Alda, MD.
Patients with unresectable hepatocellular carcinoma who have recurrent disease following surgery or locally advanced diseases who will likely progress on local therapy may have an opportunity to benefit from tremelimumab and durvalumab following its FDA approval, according to Ghassan K. Abou-Alfa, MD.
Ghassan K. Abou-Alfa, MD, discusses the importance of improving access to novel therapies and combinations for patients with hepatocellular carcinoma across the world.
Ghassan K. Abou-Alfa, MD, spoke about the recent approval of tremelimumab plus durvalumab for patients with unresectable hepatocellular carcinoma, based on results from the phase 3 HIMALAYA trial.
The combination of tremelimumab plus durvalumab improved survival for patients with unresectable hepatocellular carcinoma in the phase 3 HIMALAYA trial.
Ghassan K. Abou-Alfa, MD, examined the trial design of the phase 3 HIMALAYA trial of tremelimumab plus durvalumab for frontline hepatocellular carcinoma, with results presented at the 2022 Gastrointestinal Cancers Symposium.
Ghassan K. Abou-Alfa, MD, detailed the evolution of treatment options for unresectable hepatocellular carcinoma prior to the phase 3 HIMALAYA study and the reasons for launching the trial.
Related Content

Unusual Initial Presentation of Hepatocellular Carcinoma as a Clavicular Head Mass

August 17th 2023

Camrelizumab Combo Garners Significant PFS, OS Benefit in Unresectable HCC

July 25th 2023

FDA Accepts NDA for Rivoceranib/Camrelizumab in Unresectable HCC

July 18th 2023

Durvalumab Combo Yields Meaningful Survival Benefit in Unresectable HCC

July 6th 2023

irAEs May be Manageable With STRIDE Regimen in Unresectable Liver Cancer

June 3rd 2023

Ezurpimtrostat Receives FDA Orphan Drug Designation for Liver Cancer Subtype

February 10th 2023

Unusual Initial Presentation of Hepatocellular Carcinoma as a Clavicular Head Mass

August 17th 2023

Camrelizumab Combo Garners Significant PFS, OS Benefit in Unresectable HCC

July 25th 2023

FDA Accepts NDA for Rivoceranib/Camrelizumab in Unresectable HCC

July 18th 2023

Durvalumab Combo Yields Meaningful Survival Benefit in Unresectable HCC

July 6th 2023

irAEs May be Manageable With STRIDE Regimen in Unresectable Liver Cancer

June 3rd 2023

Ezurpimtrostat Receives FDA Orphan Drug Designation for Liver Cancer Subtype

February 10th 2023

Unusual Initial Presentation of Hepatocellular Carcinoma as a Clavicular Head Mass

August 17th 2023

Camrelizumab Combo Garners Significant PFS, OS Benefit in Unresectable HCC

July 25th 2023

FDA Accepts NDA for Rivoceranib/Camrelizumab in Unresectable HCC

July 18th 2023

Durvalumab Combo Yields Meaningful Survival Benefit in Unresectable HCC

July 6th 2023

irAEs May be Manageable With STRIDE Regimen in Unresectable Liver Cancer

June 3rd 2023

Ezurpimtrostat Receives FDA Orphan Drug Designation for Liver Cancer Subtype

February 10th 2023
Related Content
Advertisement

Unusual Initial Presentation of Hepatocellular Carcinoma as a Clavicular Head Mass

Unusual Initial Presentation of Hepatocellular Carcinoma as a Clavicular Head Mass

August 17th 2023
Article

Rohit Gupta, MD, et al review a case study of a 70-year-old man who presented with a head mass, and the final diagnosis was hepatocellular carcinoma.


Camrelizumab and rivoceranib appear to be an appropriate novel, first-line regimen for unresectable hepatocellular carcinoma.

Camrelizumab Combo Garners Significant PFS, OS Benefit in Unresectable HCC

July 25th 2023
Article

Camrelizumab and rivoceranib appear to be an appropriate novel, first-line regimen for unresectable hepatocellular carcinoma.


The new drug application for rivoceranib plus camrelizumab in unresectable hepatocellular carcinoma is supported by findings from the phase 3 CARES 310 study.

FDA Accepts NDA for Rivoceranib/Camrelizumab in Unresectable HCC

July 18th 2023
Article

The new drug application for rivoceranib plus camrelizumab in unresectable hepatocellular carcinoma is supported by findings from the phase 3 CARES 310 study.


The safety profile of durvalumab plus tremelimumab among those with unresectable hepatocellular carcinoma in the phase 3 HIMALAYA trial was comparable with the known profiles of each individual agent.

Durvalumab Combo Yields Meaningful Survival Benefit in Unresectable HCC

July 6th 2023
Article

The safety profile of durvalumab plus tremelimumab among those with unresectable hepatocellular carcinoma in the phase 3 HIMALAYA trial was comparable with the known profiles of each individual agent.


irAEs May be Manageable With STRIDE Regimen in Unresectable Liver Cancer

irAEs May be Manageable With STRIDE Regimen in Unresectable Liver Cancer

June 3rd 2023
Article

Patients with unresectable hepatocellular carcinoma receiving single tremelimumab regular interval durvalumab have a feasible immune-related adverse effect profile.


The FDA gives orphan drug designation to ezurpimtrostat, an investigational autophagy inhibitor that may benefit patients with hepatocellular carcinoma.

Ezurpimtrostat Receives FDA Orphan Drug Designation for Liver Cancer Subtype

February 10th 2023
Article

The FDA gives orphan drug designation to ezurpimtrostat, an investigational autophagy inhibitor that may benefit patients with hepatocellular carcinoma.

About
Advertise
CureToday.com
OncLive.com
OncNursingNews.com
TargetedOnc.com
Contact
Terms and Conditions
Privacy
Do Not Sell My Personal Information
Contact Info

2 Clarke Drive
Cranbury, NJ 08512

609-716-7777

© 2023 MJH Life Sciences

All rights reserved.